Carregant...
Targeted Therapy With Immunoconjugates for Multiple Myeloma
The introduction of proteasome inhibitors (PI) and immunomodulatory drugs (IMiD) has markedly increased the survival of multiple myeloma (MM) patients. Also, the unconjugated monoclonal antibodies (mAb) daratumumab (anti-CD38) and elotuzumab (anti-SLAMF7) have revolutionized MM treatment given their...
Guardat en:
| Publicat a: | Front Immunol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7316960/ https://ncbi.nlm.nih.gov/pubmed/32636838 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.01155 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|